Health officials have approved the first breast cancer drug in a decade for widespread NHS use.
Women with some forms of breast cancer are to benefit from eribulin after the National Institute for Health and Care Excellence (Nice) said it should be made available across the NHS in England.
Nice said it was able to approve the drug, also known as Halaven, after receiving new evidence about its effectiveness.
Trial results showed that it can offer women three months of additional life compared with other therapies.
Breast Cancer Now welcomed the move, saying that the drug would offer a "crucial" alternative to patients.
In draft guidance, Nice said that eribulin, made by pharmaceutical company Eisai, should be made available to women who have locally advanced or metastatic breast cancer that has spread after two rounds of chemotherapy.
Baroness Delyth Morgan, chief executive at Breast Cancer Now, said: "This is immensely positive news.
"Eribulin is the first breast cancer drug in a decade to be approved and this represents real progress for certain patients in England.
"It offers a crucial life-extending alternative for patients whose breast cancer has become resistant to other therapies, and for those with triple negative disease, who desperately lack treatment options.
"But the real tests are still yet to come and we now eagerly await Nice's decision on the even more effective drugs being appraised, including Kadcyla.
"With the appraisal process that has rejected the previous 10 breast cancer treatments seeing little meaningful reform, we unfortunately do not believe today's decision to be the beginning of a new trend."
Professor Carole Longson, director of the centre for health technology evaluation at Nice, said: "When we first looked at eribulin in 2012 there wasn't enough evidence of its clinical effectiveness compared with current standard treatments to be able to recommend it as a cost-effective use of NHS resources.
"For this appraisal we've been able to consider updated results from the trial used in the original guidance that show women taking eribulin lived on average almost three months longer compared with women taking other treatments.
"We've also been able to take into account the results for health-related quality-of-life from another trial that compared eribulin with capecitabine.
"The life expectancy of people for whom eribulin is licensed is short, and quality of life is very important.
"We are therefore pleased to be able to provisionally recommend eribulin as an additional option for people with advanced breast cancer."
The medication had previously been available through the Cancer Drugs Fund but Nice has now said it should be available routinely across the health service in England.
Patients across Wales are also likely to benefit as the Welsh NHS has been directed to implement Nice technology appraisal guidance. The Scottish Medicines Consortium (SMC) gave the drug the green light for use of the drug earlier this year.
Breast cancer is the most common cancer in women in England with around 45,000 new cases every year. Around 300 men are also diagnosed with the condition.
In 2014, 9,500 women and 60 men died from breast cancer.
Danni Manzi, head of policy and campaigns at the charity Breast Cancer Care, said: "This decision could be life-changing for many women living with incurable breast cancer.
"Access to the life-extending drug eribulin will offer patients precious extra time to spend with their loved ones. For these patients every day counts.
"We hope this decision will lay the foundation for improved access to treatments for women with this life-limiting disease. With so few treatment options available, it is momentous to bring another medicine to the table."
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here